SuspendedInterventionalPhase 2Last updated Jul 24, 2014

Spironolactone and Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients

The Role of Spironolactone in Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients

Overview

ClinicalTrials.gov ID: NCT01021943
Lead Sponsor: Instituto Nacional de Cardiologia Ignacio ChavezOTHER
Brief Summary: The main objective of this study is to assess the effect of spironolactone on interstitial fibrosis in kidney transplant recipients receiving calcineurin inhibitors
Study Type: Interventional

Status

Study Record Dates

NCT01602861Completed

The Effects of Spironolactone on Calcineurin Inhibitor Induced Nephrotoxicity

NCT02883400Completed

Spironolactone After Liver Transplant

NCT01510795Unknown status

Mineralocorticoid Receptor Antagonist and Kidney Allograft Histology

NCT02531412Unknown status

Spironolactone Administration to Prevent Ischemic Kidney Injury in Critically Ill Cancer Patients

NCT00865449Completed

Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis

NCT03329443Completed

The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography